The Experts below are selected from a list of 3693 Experts worldwide ranked by ideXlab platform
Paul Sorajja - One of the best experts on this subject based on the ideXlab platform.
-
Transcatheter repair of tricuspid regurgitation with MitraClip
Progress in cardiovascular diseases, 2019Co-Authors: Paul Sorajja, Mario Gössl, João L. Cavalcante, Richard BaeAbstract:Abstract Transcatheter Therapy with the MitraClip system (Abbott Structural, Menlo Park, CA) is the most commonly used Transcatheter Therapy for patients with tricuspid regurgitation, with over 1000 cases performed worldwide. The procedure is an off-label approach that requires meticulous attention to anatomical features obtained via comprehensive echocardiography and, in some cases, using cardiac computed tomography. Herein, we describe patient selection, procedural performance, and clinical outcomes of this Therapy.
-
Transcatheter Therapy for residual mitral regurgitation after MitraClip Therapy.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, David Lin, Desmond Jay, Paul SorajjaAbstract:AIMS We aimed to examine the effectiveness and the optimal technique for Transcatheter Therapy for residual mitral regurgitation (MR) after MitraClip Therapy with the AMPLATZER Vascular Plug II (AVP-II). METHODS AND RESULTS Nine patients (mean age, 78±4 years) underwent Transcatheter Therapy with the AVP-II for residual MR after MitraClip Therapy. We examined procedural, in-hospital, and 30-day outcomes. Our technique was successful in all cases, with treatment of different types of residual MR, including paraclip, interclip, and leaflet perforation. MR grade decreased significantly from 4+ to 1+ (p
-
Transcatheter Therapy for residual mitral regurgitation after mitraclip Therapy
Eurointervention, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, David Lin, Desmond Jay, Paul SorajjaAbstract:AIMS We aimed to examine the effectiveness and the optimal technique for Transcatheter Therapy for residual mitral regurgitation (MR) after MitraClip Therapy with the AMPLATZER Vascular Plug II (AVP-II). METHODS AND RESULTS Nine patients (mean age, 78±4 years) underwent Transcatheter Therapy with the AVP-II for residual MR after MitraClip Therapy. We examined procedural, in-hospital, and 30-day outcomes. Our technique was successful in all cases, with treatment of different types of residual MR, including paraclip, interclip, and leaflet perforation. MR grade decreased significantly from 4+ to 1+ (p<0.0001), with final residual MR being mild or none in seven patients. Mitral stenosis did not occur with plug placement. The optimal deployment technique for reduction of MR was placement with only one segment on the left atrial side of the mitral valve leaflets (n=8). During clinical follow-up (median 155 days), symptom improvement had occurred in all patients (NYHA class, baseline vs follow-up, 3.2±0.4 vs 2.3±0.8; p=0.01) with mild or no symptoms in six patients. There was no procedural mortality, major adverse event(s), device embolisation, haemolysis or need for cardiac surgery. CONCLUSIONS For patients with residual MR after MitraClip Therapy, this technique may be effective and safe, especially when deployed with only one segment on the left atrial side of the mitral leaflets.
-
Complementary Transcatheter Therapy for Mitral Regurgitation
Journal of the American College of Cardiology, 2019Co-Authors: Paul Sorajja, Richard Bae, Mario Gössl, Judah Askew, Kate Jappe, Sara Olson, Lynelle Schneider, Benjamin SunAbstract:A 77-year-old man was referred for management of mitral regurgitation (MR). The patient had a history of 2 prior coronary artery bypass surgeries and 2 aortofemoral artery grafting procedures. Six months before presentation, he underwent Transcatheter repair with percutaneous mitral valve (MV)
-
Transcatheter Therapy OF RESIDUAL MITRAL REGURGITATION AFTER MITRACLIP Therapy
Journal of the American College of Cardiology, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, Paul SorajjaAbstract:Residual mitral regurgitation (MR) after Transcatheter repair with MitraClip can be associated with persistent symptoms and impaired survival. We examined the effectiveness and the optimal technique for Transcatheter Therapy for residual MR with Amplatzer Vascular Plug (AVP) type II plugs. Nine
John P Cheatham - One of the best experts on this subject based on the ideXlab platform.
-
Shifting the Balance Between Aortic Insufficiency and Residual Gradients After Balloon Aortic Valvuloplasty
Journal of the American College of Cardiology, 2010Co-Authors: Ralf J. Holzer, John P CheathamAbstract:Since its introduction in the mid-1980s ([1][1]), Transcatheter Therapy has replaced cardiothoracic surgery as the preferred treatment modality in the majority of patients with congenital valvular aortic stenosis. In 1990, a group from Children's Hospital Boston wrote an editorial in this journal
-
congenital superior vena cava obstruction causing anasarca and respiratory failure in a newborn successful Transcatheter Therapy
Catheterization and Cardiovascular Interventions, 2005Co-Authors: Pamela S Ro, Sharon L Hill, John P CheathamAbstract:Superior vena cava (SVC) obstruction is a rare entity in the pediatric population. It usually presents in association with either previous cardiac surgery or external compression from a neoplasm. We present the case of an infant born with congenital SVC obstruction and significant bilateral chylothorax and anasarca necessitating mechanical ventilation. Successful placement of an intravascular stent led to resolution of the chylothoraces with rapid clinical improvement. © 2005 Wiley-Liss, Inc.
-
Primary Transcatheter treatment of congenital pulmonary arteriovenous malformation causing cyanosis of the newborn
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2000Co-Authors: Scott E. Fletcher, John P Cheatham, David L. BolamAbstract:We report on successful Transcatheter Therapy of congenital pulmonary arteriovenous malformation resolving persistent cyanosis and obviating the need for surgical pneumonectomy or lobectomy.
Richard Bae - One of the best experts on this subject based on the ideXlab platform.
-
Transcatheter repair of tricuspid regurgitation with MitraClip
Progress in cardiovascular diseases, 2019Co-Authors: Paul Sorajja, Mario Gössl, João L. Cavalcante, Richard BaeAbstract:Abstract Transcatheter Therapy with the MitraClip system (Abbott Structural, Menlo Park, CA) is the most commonly used Transcatheter Therapy for patients with tricuspid regurgitation, with over 1000 cases performed worldwide. The procedure is an off-label approach that requires meticulous attention to anatomical features obtained via comprehensive echocardiography and, in some cases, using cardiac computed tomography. Herein, we describe patient selection, procedural performance, and clinical outcomes of this Therapy.
-
Transcatheter Therapy for residual mitral regurgitation after MitraClip Therapy.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, David Lin, Desmond Jay, Paul SorajjaAbstract:AIMS We aimed to examine the effectiveness and the optimal technique for Transcatheter Therapy for residual mitral regurgitation (MR) after MitraClip Therapy with the AMPLATZER Vascular Plug II (AVP-II). METHODS AND RESULTS Nine patients (mean age, 78±4 years) underwent Transcatheter Therapy with the AVP-II for residual MR after MitraClip Therapy. We examined procedural, in-hospital, and 30-day outcomes. Our technique was successful in all cases, with treatment of different types of residual MR, including paraclip, interclip, and leaflet perforation. MR grade decreased significantly from 4+ to 1+ (p
-
Transcatheter Therapy for residual mitral regurgitation after mitraclip Therapy
Eurointervention, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, David Lin, Desmond Jay, Paul SorajjaAbstract:AIMS We aimed to examine the effectiveness and the optimal technique for Transcatheter Therapy for residual mitral regurgitation (MR) after MitraClip Therapy with the AMPLATZER Vascular Plug II (AVP-II). METHODS AND RESULTS Nine patients (mean age, 78±4 years) underwent Transcatheter Therapy with the AVP-II for residual MR after MitraClip Therapy. We examined procedural, in-hospital, and 30-day outcomes. Our technique was successful in all cases, with treatment of different types of residual MR, including paraclip, interclip, and leaflet perforation. MR grade decreased significantly from 4+ to 1+ (p<0.0001), with final residual MR being mild or none in seven patients. Mitral stenosis did not occur with plug placement. The optimal deployment technique for reduction of MR was placement with only one segment on the left atrial side of the mitral valve leaflets (n=8). During clinical follow-up (median 155 days), symptom improvement had occurred in all patients (NYHA class, baseline vs follow-up, 3.2±0.4 vs 2.3±0.8; p=0.01) with mild or no symptoms in six patients. There was no procedural mortality, major adverse event(s), device embolisation, haemolysis or need for cardiac surgery. CONCLUSIONS For patients with residual MR after MitraClip Therapy, this technique may be effective and safe, especially when deployed with only one segment on the left atrial side of the mitral leaflets.
-
Complementary Transcatheter Therapy for Mitral Regurgitation
Journal of the American College of Cardiology, 2019Co-Authors: Paul Sorajja, Richard Bae, Mario Gössl, Judah Askew, Kate Jappe, Sara Olson, Lynelle Schneider, Benjamin SunAbstract:A 77-year-old man was referred for management of mitral regurgitation (MR). The patient had a history of 2 prior coronary artery bypass surgeries and 2 aortofemoral artery grafting procedures. Six months before presentation, he underwent Transcatheter repair with percutaneous mitral valve (MV)
-
Transcatheter Therapy OF RESIDUAL MITRAL REGURGITATION AFTER MITRACLIP Therapy
Journal of the American College of Cardiology, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, Paul SorajjaAbstract:Residual mitral regurgitation (MR) after Transcatheter repair with MitraClip can be associated with persistent symptoms and impaired survival. We examined the effectiveness and the optimal technique for Transcatheter Therapy for residual MR with Amplatzer Vascular Plug (AVP) type II plugs. Nine
Pamela S Ro - One of the best experts on this subject based on the ideXlab platform.
-
congenital superior vena cava obstruction causing anasarca and respiratory failure in a newborn successful Transcatheter Therapy
Catheterization and Cardiovascular Interventions, 2005Co-Authors: Pamela S Ro, Sharon L Hill, John P CheathamAbstract:Superior vena cava (SVC) obstruction is a rare entity in the pediatric population. It usually presents in association with either previous cardiac surgery or external compression from a neoplasm. We present the case of an infant born with congenital SVC obstruction and significant bilateral chylothorax and anasarca necessitating mechanical ventilation. Successful placement of an intravascular stent led to resolution of the chylothoraces with rapid clinical improvement. © 2005 Wiley-Liss, Inc.
Mario Gössl - One of the best experts on this subject based on the ideXlab platform.
-
Transcatheter repair of tricuspid regurgitation with MitraClip
Progress in cardiovascular diseases, 2019Co-Authors: Paul Sorajja, Mario Gössl, João L. Cavalcante, Richard BaeAbstract:Abstract Transcatheter Therapy with the MitraClip system (Abbott Structural, Menlo Park, CA) is the most commonly used Transcatheter Therapy for patients with tricuspid regurgitation, with over 1000 cases performed worldwide. The procedure is an off-label approach that requires meticulous attention to anatomical features obtained via comprehensive echocardiography and, in some cases, using cardiac computed tomography. Herein, we describe patient selection, procedural performance, and clinical outcomes of this Therapy.
-
Transcatheter Therapy for residual mitral regurgitation after MitraClip Therapy.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, David Lin, Desmond Jay, Paul SorajjaAbstract:AIMS We aimed to examine the effectiveness and the optimal technique for Transcatheter Therapy for residual mitral regurgitation (MR) after MitraClip Therapy with the AMPLATZER Vascular Plug II (AVP-II). METHODS AND RESULTS Nine patients (mean age, 78±4 years) underwent Transcatheter Therapy with the AVP-II for residual MR after MitraClip Therapy. We examined procedural, in-hospital, and 30-day outcomes. Our technique was successful in all cases, with treatment of different types of residual MR, including paraclip, interclip, and leaflet perforation. MR grade decreased significantly from 4+ to 1+ (p
-
Transcatheter Therapy for residual mitral regurgitation after mitraclip Therapy
Eurointervention, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, David Lin, Desmond Jay, Paul SorajjaAbstract:AIMS We aimed to examine the effectiveness and the optimal technique for Transcatheter Therapy for residual mitral regurgitation (MR) after MitraClip Therapy with the AMPLATZER Vascular Plug II (AVP-II). METHODS AND RESULTS Nine patients (mean age, 78±4 years) underwent Transcatheter Therapy with the AVP-II for residual MR after MitraClip Therapy. We examined procedural, in-hospital, and 30-day outcomes. Our technique was successful in all cases, with treatment of different types of residual MR, including paraclip, interclip, and leaflet perforation. MR grade decreased significantly from 4+ to 1+ (p<0.0001), with final residual MR being mild or none in seven patients. Mitral stenosis did not occur with plug placement. The optimal deployment technique for reduction of MR was placement with only one segment on the left atrial side of the mitral valve leaflets (n=8). During clinical follow-up (median 155 days), symptom improvement had occurred in all patients (NYHA class, baseline vs follow-up, 3.2±0.4 vs 2.3±0.8; p=0.01) with mild or no symptoms in six patients. There was no procedural mortality, major adverse event(s), device embolisation, haemolysis or need for cardiac surgery. CONCLUSIONS For patients with residual MR after MitraClip Therapy, this technique may be effective and safe, especially when deployed with only one segment on the left atrial side of the mitral leaflets.
-
Complementary Transcatheter Therapy for Mitral Regurgitation
Journal of the American College of Cardiology, 2019Co-Authors: Paul Sorajja, Richard Bae, Mario Gössl, Judah Askew, Kate Jappe, Sara Olson, Lynelle Schneider, Benjamin SunAbstract:A 77-year-old man was referred for management of mitral regurgitation (MR). The patient had a history of 2 prior coronary artery bypass surgeries and 2 aortofemoral artery grafting procedures. Six months before presentation, he underwent Transcatheter repair with percutaneous mitral valve (MV)
-
Transcatheter Therapy OF RESIDUAL MITRAL REGURGITATION AFTER MITRACLIP Therapy
Journal of the American College of Cardiology, 2019Co-Authors: Hiroki Niikura, Richard Bae, Mario Gössl, Paul SorajjaAbstract:Residual mitral regurgitation (MR) after Transcatheter repair with MitraClip can be associated with persistent symptoms and impaired survival. We examined the effectiveness and the optimal technique for Transcatheter Therapy for residual MR with Amplatzer Vascular Plug (AVP) type II plugs. Nine